Social media

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

The FDA recent draft guidance sets out how Bayesian statistical methods can be applied across drug and biologics development. While Bayesian approaches have been used in medical devices and rare diseases, this is the f...

ICON’s Andrew Garrett and Tim Clark discuss the new FDA Bayesian guidance, which marks a shift toward more efficient clinical trials. https://ow.ly/XeAs50YlTf2

Join ICON at #OCT Southeast on 10–11 March to explore how we support biotech organizations with flexible clinical development solutions, operational expertise and data driven decision making. Visit Booth #37 to meet ou...

Join ICON at #OCT Southeast on 10–11 March to explore how we support biotech organizations with flexible clinical development solutions, operational expertise and data driven decision making. Visit Booth \#37 to meet o...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

Latest issue out now. Keep up to date on the latest changes with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who have discovered the convenience of this free monthly publication by signing ...

Sponsors with multi-indication assets can benefit from taking a precision approach to patient screening that enables stratification by relevant comorbidities and related factors. Learn more trial design considerations ...

At #OCT Southeast on 10–11 March, ICON will showcase the operational, scientific and digital expertise that helps biotechs navigate complexity and deliver studies with greater certainty. Visit Booth \#37 to speak with ...